Drugs / iCasp9M28z T cell infusions
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02414269 | May 2015 → Apr 2026 overdue | breast cancer, lung neoplasm, mesothelioma, metastatic neoplasm +1 | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iCasp9M28z T cell infusions | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02414269 ↗ |
| Modality | Cell therapy | “genetically modified T cells” NCT02414269 ↗ |